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ABSTRACT
Introduction: To examine the efficacy of
sitagliptin and miglitol when added to
ongoing insulin treatment in a patient with
type 2 diabetes who had undergone partial
gastrectomy.
Methods: Continuous glucose monitoring
(CGM) was performed and either sitagliptin or
miglitol, or both, were added to fixed-dose
insulin therapy. Blood was drawn at 0, 30, 60,
and 120 min after breakfast, and C-peptide,
glucagon, glucagon-like peptide (GLP)-1, and
glucose-dependent insulinotropic peptide (GIP)
were measured.
Results: CGM showed that compared to insulin
alone, the addition of either sitagliptin or
miglitol, or both, to insulin achieved better
glucose control. Compared to insulin alone,
early postprandial increments in plasma
C-peptide levels and suppressed glucagon
levels were observed when sitagliptin was
added. Glucagon suppression was even more
prominent when both sitagliptin and miglitol
were added. Compared to insulin alone, GLP-1
levels were higher during the early postprandial
stage when sitagliptin or miglitol was added and
even higher when both were added. GIP levels
decreased when sitagliptin or miglitol, or both,
were added to insulin therapy.
Conclusion: The authors showed that the
addition of sitagliptin or miglitol, or both, was
effective in this insulin-treated patient with
diabetes who had undergone gastrectomy.
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INTRODUCTION
Insulin injections are widely used as the most
dependable treatment for diabetes. The
effectiveness of insulin injections has been
established in various clinical studies.
However, an increase in insulin dosage to
achieve better glycemic control is associated
with an increased risk of hypoglycemia and
weight gain [1]. Many patients with diabetes are
being treated with insulin alone, but only a few
patients are able to achieve optimal glycemic
control with this treatment strategy. For these
patients, combination therapy with insulin
injection and oral medication is worth
considering. Incretins [2–4], glucagon-like
peptide 1 (GLP-1), and glucose-dependent
insulinotropic polypeptide (GIP) are rapidly
inactivated by the enzyme dipeptidyl peptidase
4 (DPP-4). DPP-4 inhibitors, such as sitagliptin
[5], increase active GLP-1 and GIP levels by
inhibiting DPP-4 enzymatic activity, and
improve hyperglycemia in a glucose-dependent
manner by increasing serum insulin and
decreasing serum glucagon levels in patients
with diabetes [6–10]. The safety and tolerability
of sitagliptin has been demonstrated, with a low
risk of hypoglycemia or weight gain [11].
Considering the different mechanisms and
complementary effects of sitagliptin and
insulin, a combination of these agents is a
rational treatment option for insulin-treated
patients [12]. Alpha-glucosidase inhibitors
(alpha-GIs), such as miglitol, delay the
absorption of digested carbohydrates from the
small intestine and, thus, lower both
postprandial glucose and insulin levels [13].
Alpha-GIs are considered to be effective for
stabilizing glycemic levels in patients who
have undergone gastric or esophageal
surgery because alpha-GIs prevent reactive
hypoglycemia due to late dumping syndrome
[14]. Therefore, the present study examined
the efficacy of sitagliptin and miglitol when
added to an ongoing insulin treatment in a
patient with type 2 diabetes who had
undergone partial gastrectomy. Efficacy was
estimated with the use of a continuous
glucose monitoring system (CGMS) [15–17],




The patient was a 67-year-old Japanese man
with a 15-year history of type 2 diabetes. At the
age of 55 years, the patient was diagnosed as
having gastric cancer and underwent a distal
partial gastrectomy with reconstruction via the
Billroth I operation. The patient was being
medicated with insulin lispro, which was
injected at a dose of 10, 12, and 12 units just
before breakfast, lunch, and dinner,
respectively. The patient was also injecting 12
units of insulin glargine before going to bed.
The patient had no diabetic complications, such
as neuropathy, retinopathy, or nephropathy.
The patient had concomitant hypertension,
dyslipidemia, and nontuberculous
mycobacterial infection, but all these
comorbid diseases were well controlled with
oral medication. The patient was admitted to
the authors’ hospital because of deteriorating
diabetic control. The patient’s height was
163.1 cm, and at the time of admission, body
weight was 66.9 kg (body mass index 25.2
kg/m2). Hemoglobin A1c and glycoalbumin
levels were 9.1% and 24.0%, respectively. The
urinary C-peptide level was 81.0 lg/day. The
patient provided written informed consent for
participation in the study.
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CGMS
The patient was admitted to the diabetes ward
of the authors’ hospital and was equipped with
a CGMS device (CGMS-GOLDTM; Medtronic
MiniMed, Northridge, California, USA).
The patient was monitored from 1 day before
the study to the end of the 9-day study period.
The CGMS soft sensor was changed at
the appropriate times according to the
manufacturer’s instructions. Glucose levels
measured using a self-monitoring blood
glucose device (Nipro Stat Strip XP; Nipro,
Osaka, Japan) were checked at least four times
per day for calibration of the CGMS. The
recorded data were analyzed using CGMS
Solutions software (Medtronic MiniMed,
Northridge, California, USA).
Breakfast
Breakfast with a similar number of calories each
day was served throughout the study period.
The total number of calories of a typical meal
was 428 kcal, containing 73 g of carbohydrates,
14.2 g of protein, and 7.4 g of fat. The meal was
ingested within 10–15 min.
Sample Collection and Analysis
On the first day of the study, after an overnight
fast for 14 h, an intravenous line was inserted into
one forearm vein and flushed with sterile 0.9%
NaCl solution for repeated blood sampling. Blood
was drawn at0,30, 60, and 120 min after breakfast
for the measurement of serum C-peptide, plasma
glucagon, active GLP-1, and total GIP levels.
Blood samples were immediately cooled and
centrifuged at 4 C, and plasma was stored at
-20C until analysis. Blood samples for the
determination of glucagon, active GLP-1, and
total GIP levels were collected into BDTM P800
tubes (Becton, Dickinson and Co., Franklin Lakes,
New Jersey, USA) containing spray-dried
potassium EDTA anticoagulant and a proprietary
cocktailofprotease, esterase, and DPP-4 inhibitors
(Becton, Dickinson and Co.). Plasma samples for
active GLP-1 measurements were subjected to
solid-phase extraction to remove interference
that affects immunoassays [18], and samples
were analyzed using an enzyme-linked
immunosorbent assay (ELISA) kit (Millipore
Corp., Billerica, Massachusetts, USA). Plasma
concentrations of amidated GLP-1 (7–36) and
(7–37) were measured using an antibody that is
highly specific for the N-terminus of GLP-1 and
does not react with GLP-1 (9–36), GLP-2, or
glucagon. The detection limit of the ELISA was
0.83 pmol/L, with an intra-assay coefficient of
variation (CV) of 4.06–14.90% and an interassay
CV of 11.1–13.2%. The total GIP level was
measured using a human GIP ELISA kit
(Millipore Corp.). This kit has 100% cross-
reactivity to human GIP (1–42) amide and GIP
(3–42) amide, with a detection limit of 0.50 pmol/
L, an intra-assay CV of 1.00–3.94%, and an
interassay CV of 4.99–10.10%. Both active GLP-1
and total GIP levels were measured at Mitsubishi
Chemical Medience Corp. (Tokyo, Japan). The
serum C-peptide level was measured using an
electrochemiluminescence immunoassay. Blood
samples for glucagon detection were analyzed
using a double-antibody radioimmunoassay at
SRL, Inc. (Tokyo, Japan). The area under the curve
(AUC) values for these hormones after meal
ingestion were calculated using the trapezoidal
rule.
Medications
Throughout the study period, insulin dosages
were not changed. On the first and second days
of the study (days 1 and 2), the patient used
insulin alone. From days 3 to 6, sitagliptin
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(50 mg, one tablet per day) was also taken,
before breakfast, in addition to the insulin
injections. On day 7, miglitol (50 mg, three
tablets per day) was taken before meals, in
addition to the insulin injections and
sitagliptin. From day 8 to the end of the study,
sitagliptin was discontinued, and the patient
received only insulin injections and miglitol.
Blood sampling was performed on days 2, 6, 7,
and 9. The sampling methods and timing were
identical for each blood sampling period.
RESULTS
Throughout the study period, continuous
glucose monitoring (CGM) was completed
without any problems and the patient
experienced no gastrointestinal symptoms
associated with the study medications.
Figure 1 shows the escalations and
fluctuations in glucose levels measured by
CGM during treatment with insulin alone
(days 1 and 2), insulin plus sitagliptin (days 3–6),
insulin plus sitagliptin and miglitol (day 7), and
insulin plus miglitol (days 8 and 9). The mean
and SD values of CGM measurements for days 1,
2, 3, 4, 6, 7, 8, and 9 were 185 ± 58, 210 ± 75,
154 ± 44, 157 ± 53, 158 ± 36, 144 ± 31,
137 ± 30, and 132 ± 31 mg/dL, respectively,
reflecting the attenuation of glucose
fluctuations when sitagliptin, miglitol, or
both, were added to insulin therapy.
Time-dependent changes in C-peptide,
glucagon, active GLP-1 and total GIP levels,
Fig. 1 CGM results during insulin therapy alone (days 1
and 2), insulin therapy plus sitagliptin (days 3, 4, and 6),
insulin therapy plus sitagliptin and miglitol (day 7), and
insulin therapy plus miglitol (days 8 and 9). The whole-day
result of CGM on day 5 is not available, because the
CGMS soft sensor changed. Double asterisk indicates times
of meals (this sign for dinner for day 3, and breakfast for
day 6 are missing). Single asterisk indicates times of bedtime
calibration. CGM continuous glucose monitoring, CGMS
continuous glucose monitoring system
Page 4 of 9 Diabetes Ther (2012) 3:11
123
and the AUC values of these hormones up to 2 h
after meal ingestion are summarized in Table 1
and Fig. 2. Compared to insulin alone,
remarkable early postprandial increments in
plasma C-peptide levels were observed when
sitagliptin was added to insulin therapy,
whereas no remarkable changes in
postprandial increments in plasma C-peptide
levels were observed when insulin was
administered in combination with sitagliptin
and miglitol or when insulin was administered
with miglitol only (Fig. 2a). Compared to
insulin alone, the addition of sitagliptin to
insulin therapy suppressed glucagon levels for
at least 2 h after meal ingestion. This tendency
was even more prominent when miglitol was
coadministered with sitagliptin and insulin;
however, the administration of miglitol in
combination with insulin had no observable
effect on glucagon levels during the early
postprandial phase (Fig. 2b). Compared with
insulin alone, the addition of sitagliptin or
miglitol to insulin therapy increased GLP-1
levels at least 30 min after meal ingestion.
When both sitagliptin and miglitol were added
to insulin therapy, remarkable incremental
increases in GLP-1 levels were observed. GLP-1
fluctuation in response to sitagliptin or miglitol
alone was transient, as opposed to the sustained
increase observed when both drugs were
combined with insulin (Fig. 2c). In contrast to
the GLP-1 results, GIP levels decreased when
sitagliptin or miglitol was added to insulin
therapy. This tendency was particularly
prominent when both sitagliptin and miglitol
were added to insulin therapy (Fig. 2d).
DISCUSSION
The results of the present study in a Japanese
patient with type 2 diabetes show that the
administration of sitagliptin in addition to
insulin therapy has beneficial effects on
stabilizing the fluctuating glucose levels. The
administration of miglitol in addition to insulin
therapy and the coadministration of sitagliptin
and miglitol also had beneficial effects in
lowering glycemic levels in this patient. These
effects were demonstrated precisely by the
mean ± SD values and calculated AUC values
of the glucose levels monitored by CGMS. The
authors have previously shown that the
Table 1 AUC values during the 2-h meal test
Insulin alone Insulin 1 sitagliptin Insulin 1 sitagliptin1 miglitol Insulin 1 miglitol
Glucose (CGM) AUC
(mg/dL 9 2 h)
35,345 26,265 17,588 18,528
C-peptide AUC
(nmol/L 9 2 h)
79.4 105.2 62.1 62.9
Glucagon AUC
(ng/L 9 2 h)
7,725 6,210 5,235 7,335
Active GLP-1 AUC
(pmol/L 9 2 h)
266.7 355.4 789.5 392.2
Total GIP AUC
(pmol/L 9 2 h)
9,270 5,532 1,993 4,210
AUC area under the curve, CGM continuous glucose monitoring, GIP glucose-dependent insulinotropic peptide, GLP-1
glucagon-like peptide 1
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combination of sitagliptin and miglitol was
effective for reducing glucose fluctuations and
stabilizing postprandial blood glucose levels in
patients with type 2 diabetes receiving oral
medication [19]. In the present study, the
authors have demonstrated that both single
administration and coadministration of these
two drugs was also effective in an insulin-
treated patient.
Compared to insulin therapy alone, the
addition of sitagliptin to insulin therapy was
associated with higher C-peptide and GLP-1
levels, and lower glucagon and GIP levels,
indicating that sitagliptin stimulated GLP-1
and endogenous insulin secretion, and
suppressed glucagon and GIP levels. When
miglitol was added to insulin therapy, GLP-1
levels during the early postprandial phase were
higher than those seen with insulin therapy
alone; however, unlike the case when sitagliptin
was added, glucagon levels were not suppressed.
However, GIP levels were suppressed to a level
similar to that when sitagliptin was added to
insulin therapy. These results are consistent
with previous reports, which showed that
miglitol enhances and prolongs GLP-1 release
Fig. 2 Time course of plasma C-peptide (a), glucagon (b),
active GLP-1 (c), and GIP (d) levels before and after food
intake in the patient. Thick line with ﬁlled diamond insulin
alone, dashed line with square insulin ? sitagliptin, thin line
with triangle insulin ? sitagliptin ? miglitol, dotted line
with times symbol insulin ? miglitol. GIP glucose-
dependent insulinotropic peptide, GLP-1 glucagon-like
peptide-1
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and suppresses plasma GIP secretion [20–22].
The coadministration of sitagliptin and miglitol
with insulin therapy was associated with a
significant increase in GLP-1 secretion. The
authors theoretically expected a postprandial
increment in C-peptide levels as a result of the
increased GLP-1 secretion; however, compared
to insulin therapy alone, no remarkable changes
in C-peptide levels were seen with sitagliptin
and miglitol coadministration, which may be
partly explained by the induced decrease in
blood glucose levels. In contrast, the
coadministration of sitagliptin and miglitol
with insulin therapy was associated with
significantly suppressed glucagon and GIP
levels, indicating that the combination of
these drugs acted synergistically to suppress
glucose increments.
Vilsbøll et al. [12] reported in a 24-week study
that the addition of sitagliptin to ongoing insulin
therapy resulted in significant improvements
in glycemic control by improving beta-cell
responsiveness relative to a placebo. The authors
concluded that their findings were consistent
with the mechanism of action of sitagliptin [6],
and that in patients with more advanced disease
and beta-cell failure, sitagliptin may still favorably
impact glucose-dependent insulin secretion. In
another report, Ahren et al. [23] demonstrated
that vildagliptin, another DPP-4 inhibitor,
enhanced alpha-cell responsiveness to both the
suppressive effects of hyperglycemia and the
stimulatory effects of hypoglycemia, concluding
that these effects probably contributed to the
improvement in glycemic control. Those reports
support the authors’ findings that the addition of
a DPP-4 inhibitor to insulin therapy has beneficial
effects on stabilizing glycemic control by
stimulating endogenous insulin secretion and
suppressing glucagon secretion. It is encouraging
that these favorable effects were evident in a
patient with a long history of diabetes, such as the
present patient. Inaddition, previous reports have
demonstrated that in type 1 diabetes, exogenous
GLP-1 lowered peak postprandial glucose levels
regardless of residual beta-cell function [24],
lowered fasting glycemia mainly by reducing
glucose concentration [25], and presumably
delayed gastric emptying and could normalize
glycemic excursion after a meal when given in
combination with insulin [26]. Vildagliptin has
also been reported to be beneficial for decreasing
postmeal glucagon excursion in insulinopenic
patients with type 1 diabetes; this effect was not
secondary to a change in endogenous insulin
secretion [27]. These reports encourage the use of
incretin-related agents in insulin-treated patients
with type 1 or type 2 diabetes.
In addition to sitagliptin, the addition of
miglitol to insulin therapy had favorable effects
on stabilizing glycemic control, in a patient who
had undergone gastrectomy, such as the present
patient [14]. When both sitagliptin and miglitol
were added to insulin therapy, the present patient
experienced hypoglycemia that the patient was
not completely aware of, but was revealed later by
the CGM results. Therefore, caution should be
exercised when these combinations are used
and a reduction in the insulin dose should be
considered. In other words, by adding these drugs
to insulin therapy, the authors are able to reduce
the insulin dose and are thus able to reduce the
risk of undesired side effects of insulin treatments,
such as severe hypoglycemia and increasing body
weight [28, 29].
CONCLUSION
In conclusion, with the use of CGMS, the
authors have shown that the addition of a
DPP-4 inhibitor, such as sitagliptin, was
effective in reducing glucose fluctuations and
stabilizing postprandial blood glucose levels in
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an insulin-treated patient. The addition of an
alpha-GI, such as miglitol, to insulin therapy
was also effective in this patient with diabetes
who had undergone gastrectomy. Because the
present patient was a thin man with very low
C-peptide levels and the dynamics of glucose
absorption were greatly influenced by gastric
resection, the authors are unable to apply the
present findings to a general population of
individuals with type 2 diabetes. To verify the
effectiveness of sitagliptin in insulin-treated
patients, further studies in a larger number of
patients are needed, including patients with
other insulin regimens, for instance, once-daily
injection of long-acting insulin or mixed
insulin agents two or three times daily.
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